Zacks' 7 Best Stocks for July, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/19/2013

Company Name Symbol %Change
SONIC FOUNDR SOFO
4.40%
SUPPORTCOM I SPRT
3.75%
UNISYS CORP UIS
3.31%
SHORETEL INC SHOR
3.22%
GREEN MOUNTA GMCR
3.13%

MeadWestvaco Buys AARDEX Group

by Zacks Equity Research

June 08, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

MeadWestvaco Corporation (MWV - Analyst Report) has completed the acquisition of AARDEX Group, the leader in measuring patients’ adherence to medications. The financial terms of the deal were undisclosed.

AARDEX Group is the leader in developing, manufacturing and marketing of MEMS (Medication Event Monitoring System). The system helps in measuring, analyzing and facilitating patients’ adherence to prescribed drugs and dosing regimens in clinical trials.

The acquisition was in line with the company’s strategy to fortify its leadership position and gain market share in the growing end markets. The acquisition will open the door for MeadWestvaco to foray into the fields of adherence packaging to establish a wider client base.

The company’s portfolio expanded in the complete range of packaging, data analysis and service solution that help in addressing the habit of non-adherence to medications among patients. MeadWestvaco will include MEMS into its current portfolio of adherence packaging solutions. In addition, AARDEX’s expert employee team will become the employees of MeadWestvaco.

MeadWestvaco has been implementing various policies to strengthen its position in the global packaging market along with combating the challenging market conditions. The company decided to spin-off its Consumer & Office Products segment into a new entity and merge it with ACCO Brands.

The transaction was valued at $860 million. The shareholders of MeadWestvaco received 50.5% shares of ACCO Brands while MeadWestvaco received $433 million in cash, both on a tax-free basis.

Per its strategy, MeadWestvaco had earlier completed the acquisition of Polytop Corporation to further strengthen its position in global packaging. The company now targets at achieving average annual growth of 5%-10% by leveraging its strong packaging platform.

However, the company faces severe challenges from the weak housing and labor markets in the U.S. and financial crisis in Europe. Lower consumer confidence and soft demand in some of the end markets are weighing on its margins.

MeadWestvaco faces competition from companies like International Paper (IP - Analyst Report) and WeyerhaeuserCo. (WY - Analyst Report). Currently, the stock retains a short-term Zacks #3 Rank (Hold). We have a long-term Neutral recommendation on MeadWestvaco.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.